STOCKHOLM, Feb. 5, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter 2024.
Fourth Quarter 2024
Total revenue increased 9 per cent, 8 per cent at constant exchange rates, (CER)1, to SEK 7,436 M (6,844)Haematology revenue increased 22 per cent at CER to SEK 4,487 M (3,640), mainly driven by strong sales of Doptelet® of SEK 1,147 M (727), Vonjo® of SEK 416 M (322), Aspaveli®/Empaveli® of SEK 269 M (186) and launch sales of Altuvoct® of SEK 302 M (2)Immunology revenue decreased 12 per cent at CER to SEK 2,564 M (2,905), explained by low Synagis® sales of 68 M (897), partially offset by Beyfortus® royalty of SEK 1,207 M (890) and sales of Kineret® of SEK 777 M (621)Revenue from the strategic portfolio1* grew by 50 per cent at CER to SEK 4,099 M (2,722)The adjusted EBITA margin1,2 was 34 per cent (38), excluding items affecting comparability (IAC)2. EBITA was SEK 2,572 M (2,502), corresponding to a margin of 35 per cent (37). EBIT was SEK 1,662 M (1,610)Earnings per share (EPS) before dilution was SEK 4.07 (3.02). Adjusted EPS before dilution1 was SEK 4.03 (3.21). Cash flow from operating activities was SEK 1,797 M (1,073)David Meek was elected as a new member, and as Chair of the Board of DirectorsThe information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.
RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.
Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.
On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.